DGIdb - ERCC1 Gene Record

ERCC1 2067 Clinically Actionable

Alternate Names:

2067
ERCC EXCISION REPAIR 1, ENDONUCLEASE NON-CATALYTIC SUBUNIT
ERCC1
COFS4
RAD10
UV20
126380
3433
ENSG00000012061
OTTHUMG00000182121
PA155
1735

Gene Info:

Gene Biotype	PROTEIN_CODING

(3 More Sources)

Gene Categories: Category Details

DNA REPAIR
CLINICALLY ACTIONABLE

Publications:

Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
Ceppi P et al., 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine., Ann Oncol
Yokoi M et al., 2018, Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy., Support Care Cancer
Li et al., 1998, Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells., Int. J. Oncol.
Li et al., Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line., Anticancer Res.
Goldberg et al., 2001, An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin., Int. J. Radiat. Oncol. Biol. Phys.
Li et al., Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells., Anticancer Res.
Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
Rumiato E et al., 2013, ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy., Pharmacogenet Genomics
Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
Kim HS et al., 2009, Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study., Gynecol Oncol
Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
Kawashima et al., 2011, Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer., Clin. Cancer Res.
Usanova et al., 2010, Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression., Mol. Cancer
Postel-Vinay et al., 2013, A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer., Oncogene
Cheng et al., 2013, PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells., Carcinogenesis
Rosell et al., 2006, Pharmacogenomics and gemcitabine., Ann. Oncol.
Cibeira MT et al., 2011, Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide., Leuk Res
Bosó V et al., 2014, SNPs and taxane toxicity in breast cancer patients., Pharmacogenomics
Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
Cheng L et al., 2017, Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression., Mol Carcinog
Fujishima et al., 1997, Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line., Oncol. Res.
Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J

PLATINUM ERCC1

Interaction Score: 3.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB
PALONOSETRON ERCC1

Interaction Score: 2.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29177570

Sources:
PharmGKB
OXALIPLATIN ERCC1

Interaction Score: 1.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 27498158 25069034 23314736 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB
CISPLATIN ERCC1

Interaction Score: 0.7

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9772291 9703867 11163512 10810335 29662106 27498158 25069034 23962907 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 19203783 18347182 21177407 20846399 23934192 23275151 17229776 16980606 16807441

Sources:
NCI CIViC PharmGKB
CARBOPLATIN ERCC1

Interaction Score: 0.6

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB
GRANISETRON ERCC1

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29177570

Sources:
PharmGKB
LEUCOVORIN ERCC1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23314736 21057378

Sources:
PharmGKB
FLUOROURACIL ERCC1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28796378 23314736 21057378 9268987

Sources:
NCI PharmGKB
THALIDOMIDE ERCC1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21435719

Sources:
PharmGKB
CAPECITABINE ERCC1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25026457

Sources:
PharmGKB
BLEOMYCIN ERCC1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GEMCITABINE ERCC1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17229776 16980606

Sources:
CIViC PharmGKB
PACLITAXEL ERCC1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25495407 17229776

Sources:
CIViC PharmGKB
CYCLOPHOSPHAMIDE ERCC1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22188361 19786980

Sources:
PharmGKB
DOCETAXEL ERCC1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25495407

Sources:
PharmGKB
ETOPOSIDE ERCC1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN ERCC1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000012061
- Version: 101_38
Alternate Names:

ERCC1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

PharmGKB: ERCC1

Version: 18-August-2020

Alternate Names:

PA155 PharmGKB ID

Gene Info:

Publications:

Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics

Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol

Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J

CIViC: ERCC1

Version: 14-September-2020

Alternate Names:

2067 Entrez Gene ID

1735 CIViC Gene ID

Gene Info:

Publications:

Ceppi P et al., 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine., Ann Oncol

Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol

Rosell et al., 2006, Pharmacogenomics and gemcitabine., Ann. Oncol.

NCI: ERCC1

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Goldberg et al., 2001, An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin., Int. J. Radiat. Oncol. Biol. Phys.

Li et al., 1998, Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells., Int. J. Oncol.

Li et al., Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells., Anticancer Res.

Tempus: ERCC1
- Version: 11-November-2018
Alternate Names:

ERCC1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: ERCC1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
GO: ERCC1
- Version: 01-February-2022
Alternate Names:

Gene Info:

Gene Categories:

DNA REPAIR

Publications:

ERCC1 Gene Record

ERCC1 2067 Clinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29177570

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 27498158 25069034 23314736 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9772291 9703867 11163512 10810335 29662106 27498158 25069034 23962907 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 19203783 18347182 21177407 20846399 23934192 23275151 17229776 16980606 16807441

Sources: NCI CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29177570

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23314736 21057378

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28796378 23314736 21057378 9268987

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21435719

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25026457

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17229776 16980606

Sources: CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25495407 17229776

Sources: CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22188361 19786980

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25495407

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Ensembl: ENSG00000012061

Alternate Names: ERCC1 Ensembl Gene Name

Gene Info: Gene Biotype PROTEIN_CODING

Publications:

PharmGKB: ERCC1

Alternate Names: PA155 PharmGKB ID

Interaction Types & Directionality:

n/a

PMIDs:
29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29177570

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29662106 27498158 25069034 23314736 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9772291 9703867 11163512 10810335 29662106 27498158 25069034 23962907 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 19203783 18347182 21177407 20846399 23934192 23275151 17229776 16980606 16807441

Sources:
NCI CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29177570

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23314736 21057378

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28796378 23314736 21057378 9268987

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21435719

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25026457

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17229776 16980606

Sources:
CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25495407 17229776

Sources:
CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22188361 19786980

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25495407

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Alternate Names:

ERCC1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

PA155 PharmGKB ID

Alternate Names:

2067 Entrez Gene ID

1735 CIViC Gene ID

Alternate Names:

ERCC1 Gene Symbol

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

DNA REPAIR